Reductions in breast cancer risk for women with a hysterectomy receiving oestrogen-alone therapy have persisted since termination of active treatment on the Women's Health Initiative trial. The few deaths among women diagnosed with breast cancer during this trial limit the interpretation of the reduced mortality for women receiving oestrogen alone compared with placebo.
